pf-02545920
Showing 1 - 10 of 10
Schizophrenia Trial in Glendale (PF-02545920, Placebo)
Completed
- Schizophrenia
- PF-02545920
- Placebo
-
Glendale, CaliforniaCalifornia Clinical Trials Medical Group
Nov 20, 2017
Schizophrenia, Schizo-affective Disorder Trial in George (PF-02545920)
Completed
- Schizophrenia
- Schizo-affective Disorder
- PF-02545920
-
George, South AfricaPfizer Investigational Site
Sep 4, 2018
Huntington's Disease Trial in Paris Cedex 13 (PF-02545920, Placebo)
Completed
- Huntington's Disease
- PF-02545920
- Placebo
-
Paris Cedex 13, FranceCentre d'Investigation Clinique (CIC)/ Institut du Cerveau et de
May 8, 2017
Huntington's Disease Trial in Worldwide (PF-02545920, Placebo)
Completed
- Huntington's Disease
- PF-02545920
- Placebo
-
Birmingham, Alabama
- +56 more
Oct 13, 2017
Healthy Trial in Huddinge (20 mg PF-02545920, PF-02545920)
Completed
- Healthy
- 20 mg PF-02545920
- PF-02545920
-
Huddinge, Stockholm, SwedenKarolinska Trial Alliance (KTA) M62
Nov 6, 2014
Healthy Trial in New Haven (Saline, PF-02545920, Ketamine)
Terminated
- Healthy
- Saline
- +3 more
-
New Haven, Connecticut
- +2 more
Mar 19, 2014
Healthy Trial in New Haven (PF-02545920, , Placebo)
Completed
- Healthy
- PF-02545920
- +2 more
-
New Haven, Connecticut
- +2 more
Nov 11, 2011